Review finds limited drug evidence and calls for stronger trials
Current perspectives in the pharmacological treatment of gambling disorder: psychedelics and beyond.
AI Summary
This narrative review asks what pharmacological approaches may help treat gambling disorder (GD), a behavioral addiction, and assesses established and emerging options. It searched English-language literature published from January 2010 to January 2026. The review reports that opioid antagonists have the most consistent, though still limited, therapeutic signal, with possible benefits in selected patients who experience prominent gambling urges. Findings for antidepressants, mood stabilizers, antiepileptic drugs, and antipsychotics are mixed.
The review also discusses experimental approaches involving glutamatergic, noradrenergic, endocannabinoid, and orexin-related mechanisms, along with psychedelics and other neuroplasticity-oriented treatments such as psilocybin, ketamine/esketamine, and MDMA-assisted interventions. These approaches are described as promising, not established treatments. The authors call for adequately powered, controlled, and longitudinal trials and suggest research move toward treatment tailored to patient characteristics. As a narrative review, this abstract does not establish that any intervention is effective; it provides no quantitative trial results or sample sizes.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
Meta-analysis finds shared endocannabinoid gene changes across myopathies
Small biomarker analysis finds no significant changes after 10 HBOT sessions
Rat study finds mixed behavioral and biological effects of WIN under chronic…
Explore More Research
Stay informed about the latest cannabis science.